Your session is about to expire
← Back to Search
Abatacept Injection for Juvenile Idiopathic Arthritis (Limit-JIA Trial)
Limit-JIA Trial Summary
This trial will test whether a weekly injection of abatacept can help prevent Juvenile Idiopathic Arthritis from progressing to a more severe form.
Limit-JIA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLimit-JIA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Limit-JIA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My arthritis affects 4 or fewer joints since it started.I am between 2 and 16.5 years old.My arthritis affects 4 or fewer joints since it started.My primary language is not English or Spanish.I have been diagnosed with inflammatory bowel disease.I have not taken long-term steroids in the last 30 days, except for a short course.I have a kidney condition.I have a history of liver disease.My liver and kidney tests are within normal limits.I have had or currently have uveitis.I have taken medication for juvenile arthritis before.I plan to switch to a new rheumatologist not in this study within a year.I was diagnosed with juvenile arthritis by a specialist in the last 6 months.I have inflammation in my lower back joints.I have or currently suffer from psoriasis.I have not had a live virus vaccine in the last month.I haven't had a serious infection or needed strong antibiotics recently.I have been diagnosed with systemic juvenile idiopathic arthritis.I have or had cancer.I weigh less than 10 kilograms.I weigh at least 50 kg and have agreed to join the Limit-JIA study.
- Group 1: Abatacept and Usual Care (Part II)
- Group 2: Active Comparator: Usual Care (Part I)
- Group 3: Abatacept and Usual Care (Part I)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Abatacept Injection met the FDA's standards for approval?
"Abatacept Injection's safety is supported by multiple rounds of clinical data, giving it a score of 3."
Are there still positions available for volunteers in this experiment?
"Yes, this trial is still open and recruiting patients. 28 different hospitals or clinics are participating in the study, which was first posted on October 29th, 2019. The most recent update to the trial's information was on August 16th, 2022 and the goal is to have 130 people enrolled by the end of recruitment."
Are there other instances where Abatacept Injection has been studied?
"Abatacept Injection was first researched in 2007 at University of Nebraska Medical Center. As of now, there are 453 completed studies and 36 ongoing clinical trials. A majority of these active investigations are taking place in Minneapolis, Minnesota."
What are some common indications for Abatacept Injection?
"Abatacept Injection is frequently used to mitigate the effects of rheumatoid arthritis. However, it can also be given to patients suffering from psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and severe juvenile idiopathic arthritis."
May I be a subject in this clinical trial?
"Eligible participants for this arthritis clinical trial must be between 2 and 16 years old, have arthritis affecting 4 or fewer joints, a history of psoriasis or currently active psoriasis, and weigh 50 kg or more (only at Canadian sites). To enroll in the Limit-JIA study, patients must sign a consent form."
How many individuals are being observed in this clinical trial?
"That is correct. The clinical trial in question, which was first posted on October 29th 2019, is still recruiting patients across 28 sites. So far, 130 people have enrolled in the study."
Could you inform me how many hospitals are administering this trial at the present time?
"Patients are being enrolled at various hospitals and clinics including University of Minnesota; Children's Hospital and Clinics of Minnesota in Minneapolis, Minnesota, The Pediatric Specialty Center at Saint Barnabas/RWJ Barnabas Health in West Orange, Washington, Seattle Children's Hospital in Seattle, Illinois , and 28 other locations."
Does this clinical trial have an age limit? If so, what is it?
"Eligible applicants for this trial must be between 2 and 16 years old. Out of the total428 clinical trials, 67 focus on pediatrics while 361 are for geriatrics."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger